Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen - Takeaways - MDSpire

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen

  • By

  • Shai Shimony

  • Hari S. Raman

  • Yael Flamand

  • Julia Keating

  • Jonathan D. Paolino

  • Yannis K. Valtis

  • Andrew E. Place

  • Lewis B. Silverman

  • Stephen E. Sallan

  • Lynda M. Vrooman

  • Andrew M. Brunner

  • Donna S. Neuberg

  • Ilene Galinsky

  • Jacqueline S. Garcia

  • Eric S. Winer

  • Martha Wadleigh

  • Richard M. Stone

  • Jean M. Connors

  • Daniel J. DeAngelo

  • Marlise R. Luskin

  • October 31, 2024

  • 0 min

Share

  • 1

    Adolescent and young adult patients with acute lymphoblastic leukemia may experience a 5% to 34% incidence of venous thromboembolism when treated with asparaginase.

  • 2

    Asparaginase treatment is associated with increased risk for venous thromboembolism due to decreased synthesis of anticoagulant proteins.

  • 3

    A retrospective study included 341 patients, revealing that 33.4% experienced at least one venous thromboembolism event during treatment.

  • 4

    Higher body mass index was associated with increased rates of venous thromboembolism in patients with acute lymphoblastic leukemia.

  • 5

    The study aimed to evaluate the prevalence, risk factors, and clinical impact of venous thromboembolism in adolescents and young adults with ALL.

Original Source(s)

Related Content